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Pseudoxanthoma elasticum (PXE) is a
multisystem disorder manifesting pri-
marily with clinical findings in the skin,
the eyes, and the cardiovascular system,
with considerable morbidity and occa-
sional mortality (Neldner, 1988; Uitto
et al., 2010). The precise prevalence of
PXE is currently unknown, but it is
clearly a rare disease. Nevertheless, the
prevalence has been suggested to be
B1:50,000, which would imply that
there are B7,000 affected individuals
in the United States and as many as
150,000 in the world assuming the same
global prevalence (Uitto, 2012). PXE is
inherited in an autosomal recessive
manner caused by mutations in the
ABCC6 gene that encodes ATP-Binding
Cassette, family C, number 6 protein,
ABCC6. This transmembrane efflux
transporter is expressed primarily in the
liver, and to some extent in the kidneys
and the intestine, but at very low levels,
if at all, in tissues directly affected by
PXE. Previous observations on patients
with PXE, as well as studies utilizing a
knockout mouse model, Abcc6 / , as
a platform, have suggested that PXE is a
metabolic disorder with primary
molecular defect in the liver; however,
the precise pathomechanistic details
leading from ABCC6 mutations to
mineralization of peripheral tissues are
currently unknown. There is no effective
and specific treatment of systemic
manifestations available for this
currently intractable disorder.
The principal researchers working on
PXE from laboratories around the world
convened in Bethesda, Maryland, USA,
on 24 and 25 September 2012, to parti-
cipate in the biennial research meeting
organized by PXE International, the pre-
mier lay organization advocating on
behalf of PXE patients and their families
(Terry et al., 2007). The Organizing
Committee consisted of the authors of
this publication, and the list of partici-
pants is in Supplementary Information 1
online. The presentations and ensuing
discussions provided state-of-the-art, up-
to-date information on epidemiology,
diagnostics, pathomechanisms, and
treatment potential relating to PXE, with
translational implications. The progress
in research, as reflected by the 2012
PXE International Research Meeting, is
summarized here with emphasis on
advances made since the previous simi-
lar meeting in 2010 (Uitto et al., 2011).
Novel genes, unusual phenotypes
Since the identification of the ABCC6 as
the gene harboring mutations in patients
with PXE, the mutation database has
expanded to consist of close to 600
distinct mutations representing well over
1,000 mutant alleles (http://www.ncbi.
nlm.nih.gov/lovd/home.php?select_db=
ABCC6). Some of these mutations are
recurrent, including p.R1141X and
g.del23-29, which account for up to
B40% of all mutations. With stream-
lined and targeted mutation detection
strategies, over 90% of the families with
PXE can now be shown to harbor
mutations in the ABCC6 gene. It should
be noted that improvements in sequen-
cing technologies and introduction of
new strategies, such as genome and
whole-exome sequencing, could iden-
tify novel mutations in ABCC6 as well as
in candidate genes potentially modify-
ing the PXE phenotype.
Clinical observations of the presence
of PXE-like cutaneous features asso-
ciated with unusual phenotypes have
revealed additional mutated genes
(Table 1). First, skin manifestations remi-
niscent of PXE were noted in families
with unusually loose and lax skin sug-
gestive of cutis laxa, in association with
vitamin K–dependent coagulation factor
deficiency manifesting with a bleeding
disorder (Vanakker et al., 2007; Li et al.,
2009c). Examination of these patients
revealed mutations in the GGCX gene
encoding vitamin K–dependent g-gluta-
myl carboxylase, which catalyzes g-
carboxylation of glutamyl residues in a
number of proteins (so-called Gla pro-
teins), including several coagulation fac-
tors and matrix gla protein (MGP)
(Berkner, 2005). The synergism of the
ABCC6 and GGCX genes has also been
demonstrated in a family in which
patients with typical clinical cutaneous
findings of PXE and characteristic histo-
pathology were shown to be compound
heterozygous for one mutation in the
GGCX gene and another one in the
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ABCC6 gene, suggesting digenic
inheritance (Li et al., 2009a).
Intriguing observations relating to the
postulated mineralization/antiminerali-
zation networks is provided by general-
ized arterial calcification of infancy
(GACI), an autosomal recessive disorder
with a phenotypic overlap with PXE in
the form of vascular mineralization
(Rutsch et al., 2011). However, these
two conditions are clinically distinct, as
vascular mineralization in PXE is of late
onset, whereas GACI patients demon-
strate a severe mineralization of arterial
blood vessels prenatally or at birth,
frequently leading to the demise of the
affected individuals during the first year
of life from myocardial infarcts or car-
diac insufficiency. GACI has previously
been shown to be caused by mutations
in the ENPP1 gene, but mutation analy-
sis has been unsuccessful in finding
mutations in this gene in B20% of
patients, suggesting genetic hetero-
geneity (Kalah et al., 2012). Quite
recently, mutations in the ABCC6 gene
have been shown to underlie the GACI
phenotype in several families (Nitschke
et al., 2012; Li et al., 2012b). A sur-
prising finding was that many of these
mutations have been previously shown
to cause PXE in unrelated families,
raising the question of the potential
role of modifier genes in determining
the mineralization phenotype as a result
of ABCC6 mutations. It should also be
noted that there has been a report of one
family in which one of the siblings died
in infancy with clinical findings
consistent with GACI, whereas another
sibling developed late-onset manifesta-
tions of PXE, which was subsequently
shown to be associated with mutations
in the ABCC6 gene (Le Boulanger et al.,
2010). A related observation attesting to
the clinical overlap of PXE and GACI is
in a report describing a 2-year-old
patient with clinical findings of vas-
cular calcification consistent with
GACI, and with characteristic cutane-
ous findings of PXE (Li et al., 2012c).
This patient was shown to harbor
mutations in the ENPP1 gene. Thus,
mutations in the ENPP1 and ABCC6
genes can result in ectopic minerali-
zation with the phenotypic overlap
between GACI and PXE, attesting to the
spectrum of ectopic mineralization
disorders, possibly as a result of conver-
gent mineralization pathways because of
underlying mutations in different genes.
In addition to ABCC6 and ENPP1, a
number of other genes can harbor muta-
tions resulting in ectopic mineralization
in the skin and arterial blood vessels,
supporting the notion of an intricate
mineralization/antimineralization net-
work in tissues (Table 1). Thus, careful
balance of factors both promoting and
preventing connective tissue mineraliza-
tion at the local level is required for
normal homeostasis (Rutsch et al., 2011).
Model systems
Following the identification of ABCC6
as the gene harboring mutations in PXE,
two targeted knockout mouse models
were developed (Gorgels et al., 2005;
Klement et al., 2005). These mice
recapitulate the features of PXE by
developing late-onset, progressive
mineralization similar to that seen in
human patients, and the mineral
deposits in these mice, similar to PXE
patients, have been shown to consist of
hydroxyapatite (Kavukcuoglu et al.,
2012). A unique finding in these mice
is mineralization of the dermal sheath of
vibrissae in the muzzle skin as an early
sign and reliable biomarker of the
overall progress of mineralization
process. This specialized hair follicle
type in mouse muzzle skin is not
found in humans, and mineralization
of the vibrissae dermal sheath is very
unusual in mice. However, a recent
large-scale, in-depth study of 31 inbred
strains of mice conducted at The
Jackson Aging Center (Bar Harbor, ME)
identified an inbred mouse strain, the
KK/HlJ mouse, with dermal sheath
mineralization similar to that noted in
Abcc6 / mice (Sundberg et al., 2011).
It has been shown that the KK/HlJ mice
harbor a spontaneous, nonsynonymous,
single-nucleotide polymorphism (SNP),
which not only substitutes arginine by
cysteine at position 621 (p.R621C) but
also interferes with splicing of the Abcc6
pre-mRNA, resulting in reduced Abcc6
protein levels in the liver, the primary
site of the expression of the gene (Li
et al., 2012a). Subsequent mouse
database genome analysis revealed
that, in addition to KK/HlJ mice, three
other inbred strains, 129S1/SvlmJ, C3H/
HeJ, and DBA/2J, have the same Abcc6
Table 1. Heritable disorders of ectopic mineralization with pathogenic mutations in candidate genes
Disease
Predominant organ
involvement Characteristic clinicopathological features Mutated genes
PXE Skin, eyes, arteries Late-onset, slowly progressive mineralization; loss of visual acuity ABCC61, ENPP1
PXE-like cutaneous
findings
Skin Mineral deposits in mid-dermis; loose and sagging skin GGCX
GACI Arterial blood vessels Prenatal or early postnatal mineralization; demise o1 year of age ENPP11, ABCC6
CD73 deficiency Arterial blood vessels Calcification of lower extremity arteries, hand, and feet joint capsules NT5E
FTC Skin and subcutis
Normophosphatemic Erythematous rash and mucosal inflammation; small, acral calcified nodules
with ulceration
SAMD9
Hyperphosphatemic Slowly growing calcified masses in periarticular locations; ulcerations and pain GALNT3, FGF23,
KL
Abbreviations: FTC, familial tumoral calcinosis; GACI, generalized arterial calcification of infancy; PXE, pseudoxanthoma elasticum.
1The majority of mutations are found in these genes. However, mutations in the ENPP1 and/or ABCC6 genes have also been demonstrated in these two
conditions, with considerable clinical overlap (see text).
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allelic mutation as the KK/HlJ mice but
with highly variable mineralization
phenotypes (Berndt et al., 2012). Thus,
these inbred mouse strains represent
novel spontaneous PXE models, and
they are most suitable to apply stan-
dard mouse genetics to identify modifier
genes for ectopic mineralization by
genome-wide association studies and
quantitative trait locus analyses.
Novel model systems, both in vitro
and in vivo, have also been developed
to examine the consequences of mis-
sense disease-causing mutations in the
ABCC6 gene, with respect to functional
transporter activity and intracellular traf-
ficking of the mutant protein. For exam-
ple, the biochemical transport properties
have been determined in vitro in Sf9
insect cell membrane vesicles that were
transfected to express human ABCC6
gene. The cellular localization of each
variant can also be determined in vitro
in polarized MDCKII cells, as well as
in vivo in mouse liver utilizing hydro-
dynamic tail vein injection (Le Saux
et al., 2011). However, these studies
indicated that many of the disease-
causing mutations resulted in impaired
cellular processing and aberrant
intracellular localization, with intact
transport function. These mutants
appear to be suitable candidates for
pharmacological correction by
chaperones or small molecules, such
as sodium 4-phenylbutyrate, modifiers
of protein conformation that would
potentially allow targeting of the
protein to the plasma membrane.
These studies have also been correla-
ted with the assessment of the functional
activity of ABCC6 protein in a zebrafish
model. Specifically, it has been pre-
viously shown that Abcc6a gene
expression is required for normal deve-
lopment of zebrafish embryos, as demon-
strated by morpholino knockdown (Li
et al., 2010). The mutant phenotype can
be rescued by concomitant injection of
human ABCC6 mRNA, and thus this
model provides a system to test the
functional activity of ABCC6 mutants in
an mRNA rescue assay.
Pathomechanistic pathways
The observation of deficiency in the
vitamin K–dependent g-glutamyl car-
boxylase activity, and reduction in the
g-glutamyl carboxylation of matrix
MGP, a powerful local antimineraliza-
tion factor when in fully carboxylated
form, suggested a role for vitamin K
deficiency in contributing to the PXE
phenotype. Specifically, it was hypothe-
sized that deficiency of vitamin K or one
of its derivatives could contribute to
PXE phenotype through deficient g-glu-
tamyl carboxylation of MGP (Borst
et al., 2008). This hypothesis has been
tested in a number of laboratories by
the administration of vitamin K to
Abcc6 / mice, which, however, did
not counteract the aberrant minerali-
zation of connective tissues (Brampton
et al., 2011; Gorgels et al., 2011; Jiang
et al., 2011). Furthermore, it was shown
that ABCC6 does not transport vitamin
K3–glutathione conjugate from the
liver to circulation (Fu¨lo¨p et al., 2011).
Thus, the role of vitamin K in the
pathogenesis of PXE, if any, remains
unclear.
The role of vitamin K has also been
examined by feeding Abcc6 / mice
with warfarin, a commonly used antic-
oagulant that interferes with the vitamin
K cycle by preventing the reduction of
oxidized vitamin K (epoxide) to its
reduced form (hydroquinone). Clinical
use of warfarin has been reported to be
associated with increased mineraliza-
tion of the arterial blood vessels and
cardiac valves (Palaniswamy et al.,
2011). Therefore, it was hypothesized
that warfarin may accelerate the
ectopic tissue mineralization in PXE,
with clinical consequences (Li et al.,
2013). In these experiments, warfarin
clearly interfered with the vitamin K
cycle, as demonstrated by significantly
increased plasma levels of the oxidized
vitamin K. Examination of the mice
placed on a warfarin-containing diet
by quantitative histopathology revealed
massive accumulation of mineral
deposits, which were shown to consist
of hydroxyapatite, in the dermal
sheath of vibrissae, kidneys, heart,
aorta, and eyes, well beyond the levels
noted in Abcc6 / mice kept on
control diet. As previous studies have
suggested that MGP is a powerful
antimineralization factor that has a role
in PXE, these results suggested
that reduction in the g-carboxylation of
MGP as a result of warfarin treatment
allowed progressive mineralization to
ensue. Thus, patients with PXE may be
at risk for increased ectopic minerali-
zation and severity of their disease
as a result of warfarin therapy (Li et al.,
2012c).
In 2012, just before the meeting, a
provocative paper was published, sug-
gesting novel pathomechanistic consid-
erations for PXE (Martin et al., 2012).
Specifically, it was suggested that
ABCC6, rather than being present in
the plasma membrane of hepatocytes,
localizes intracellularly to the
mitochondria-associated membranes
(MAMs). The authors suggested that,
given the major role of the MAM in
calcium signaling, lipid metabolism,
and secreted protein processing, their
findings may lead to new approaches for
establishing the connection between
ABCC6 and tissue calcification. This
paper was carefully addressed in more
recent, still unpublished studies presen-
ted by different investigators in the
meeting. For example, it was noted
that careful immunohistochemical
localization studies of ABCC6, with
concomitant markers of the plasma
membranes, provide evidence of colo-
calization of these proteins (V Pomozi
et al., personal communication). There-
fore, the conclusions of the paper sug-
gesting the association of ABCC6 with
MAM await independent confirma-
tion from other laboratories. It should
be noted, however, that if the postulate
that ABCC6 is a MAM-associated
protein, rather than a plasma mem-
brane efflux transporter, is correct, this
would fundamentally change many of
the considerations for pathomechanistic
details and further development of
treatment modalities for PXE.
Phenotypic modulation
PXE is characterized by considerable
intra- and inter-familial heterogeneity
with respect to the age at onset, the
degree of tissue mineralization, and the
severity of organs affected, suggesting a
role for genetic and environmental mod-
ifying factors. As indicated above, the
role of genetic factors is clearly attested
to by the existence of mouse strains that
harbor the same pathogenetic Abcc6
mutation, yet the mineralization pheno-
type is highly variable (Berndt et al.,
J Uitto et al.
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2012). In patients with PXE, careful
examination of the existing mutation
database with respect to the types and
combinations of mutations and the
accompanying clinical manifestations
have not revealed definitive genotype/
phenotype correlations, again sugges-
ting genetic or environmental modu-
lation of this phenotype (Pfendner
et al., 2007).
A large cohort of German PXE
patients with age- and sex-matched
healthy controls were examined with
respect to selected functional SNPs in
candidate genes, known to encode pro-
teins, which act in regulation of matrix
calcification, degradation, and/or angio-
genesis (D Hendig et al., unpublished).
This study identified several functional
polymorphisms statistically associated
with PXE manifestations (SPP1, ENPP1,
and VKORC1), PXE severity (VEGFA),
and the progressive course of the dis-
ease (different antioxidant genes). Inter-
estingly, a haplotype arising from two
promoter polymorphisms, c.-7G-A
and c.-138T-C, in the MGP gene was
more frequently detected in the control
cohort, and therefore was postulated to
be a potential protective factor in PXE
manifestations.
Gender differences in PXE
manifestations
Early clinical observations suggested
that there is considerable overrepresen-
tation of women with PXE, a curious
observation in an autosomal recessive
disease with apparently complete pene-
trance. To address this issue, gender
differences in PXE were recently
explored by a questionnaire submitted
to the patients in the PXE International
database. A total of 393 women and
120 men affected by PXE completed a
questionnaire inquiring about clinical
signs and symptoms, as well as age at
presentation and diagnosis, past treat-
ments, and family history. The results
revealed that women were disproportio-
nately represented in the database,
among respondents and affected sib-
lings; however, women comprised a
significantly larger portion of respon-
dents than that of their affected siblings
(L Bercovitch et al., unpublished).
Women are more likely to have skin
findings in all sites affected by PXE,
whereas men tend to have more severe
vision loss, experience retinal bleeding
earlier, and they are more likely to
become legally blind. Men are signifi-
cantly more likely to have angina and
require coronary bypass surgery or
angioplasty. They had significantly more
hyperlipidemia and a higher mean body
mass index. There was no significant
difference in reported rates of peripheral
vascular disease. Although the limita-
tions of this epidemiological study
included the fact that the data were
self-reported, rather than based on phy-
sical examination, it appears that PXE
disproportionately affects women, and
some, but not all, of this difference can
be attributed to self-selection bias. The
apparent disproportion in the number of
women and men that are affected
remains unexplained. A better under-
standing of the factors that account for
the differences in severity of the ocular
and cardiovascular phenotypes in
men and women might be of value
in devising strategies for prevention of
complications.
Toward treatment
No specific or effective treatment is
currently available for the systemic
mineralization phenotype in PXE. How-
ever, significant progress has been made
in the treatment of ocular complications
by intravitreous injection of vascular
endothelial growth factor antagonists
that prevent neovascularization, the
cause of loss of visual acuity and blind-
ness in many cases of PXE (Georgalas
et al., 2011). For systemic manifesta-
tions, mouse studies feeding Abcc6 /
mice with magnesium have suggested
that dietary modifications may be
helpful for the prevention of PXE com-
plications. Specifically, increasing the
magnesium content of the mouse diet
5-fold over the concentration in
standard diet has been shown to com-
pletely prevent the ectopic minerali-
zation in these animals (LaRusso et al.,
2009; Gorgels et al., 2011). Further-
more, magnesium oxide containing
phosphate binders have been shown to
have similar effects (Li et al., 2009b).
Conversely, recent studies have demon-
strated that reduction of magnesium
intake accelerates the mineralization
process in PXE mice (Jiang and Uitto,
2012).
On the basis of these preclinical
observations in Abcc6 / mice, a dou-
ble-blinded clinical trial has now been
initiated to test the efficacy of dietary
magnesium, 900 mg per day, for the
clinical outcome and histopathologi-
cally demonstrable mineralization in a
cohort of patients with PXE (Dr Mark
Lebwohl, Mt Sinai University School
of Medicine, New York; http://clinical
trials.gov/show/NCT01525875). The cur-
rently recommended daily dose of
magnesium by the Food and Drug
Administration is 425 mg per day for an
adult, and thus the study slightly more
than doubles this level. In this context, it
should be noted that there is currently no
reliable biomarker to follow the progress
of the mineralization phenotype in PXE
beyond clinical observations and skin
biopsy, and consequently this study is
extended to up to 2 years. However,
recent studies have suggested that mea-
surements of carotid intima-media thick-
ness (CIMT), a risk factor for cardio-
vascular disease and stroke, might pro-
vide such a biomarker for clinical trials.
To this aim, the feasibility of CIMT as a
treatment end point before and after
magnesium supplementation was tested
in Abcc6-/- mice fed standard rodent diet
with or without magnesium oxide sup-
plementation (Kupetsky-Rincon et al.,
2012). Baseline CIMT was significantly
higher in Abcc6 / than in Abcc6þ /þ
mice, whereas CIMT was significantly
lower in magnesium-treated Abcc6 /
mice than in untreated Abcc6 / mice.
These observations suggest that CIMT
may serve as a novel predictive
biomarker of therapeutic response in
PXE patients in future clinical trials.
In addition to attempts to modify the
phenotypic outcome by reducing the
deposits of mineral in tissues by dietary
modulation, different molecular approa-
ches have been considered to correct
the ABCC6 deficiency in PXE. Toward
this aim, analysis of the transcriptional
regulation of ABCC6 gene expression
identified DNaseI hypertensive sites
(HSs) specific to cell lines expressing
ABCC6. These sites are located in the
proximal promoter and in the first intron
of the gene. It was further demonstrated
that hepatocyte nuclear factor 4a
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(HNF4a) and CCAAT/enhancer binder
protein b (C/EBPb) bind to the proximal
promoter and the primate-specific sec-
ond intronic HS. These results suggested
that C/EBPb forms a complex with other
regulatory proteins, including previously
identified regulatory factor HNF4a (De
Boussac et al., 2010; Ratajewski et al.,
2012). These data attest to the complex
tissue- and primate-specific expression
of the ABCC6 gene, a topic that was
also addressed by the keynote speaker,
Dr La´szlo´ Nagy, University of
Debrecen, Hungary.
The potential treatment of PXE has
also recently been explored by a num-
ber of molecular and cell-based strate-
gies. For example, transplantation of
cells with hepatoblastic lineage differ-
entiation, either representing a hepato-
blast cell line or differentiated from
induced pluripotent stem cells (iPSCs),
has demonstrated homing of these cells
to the liver and has resulted in Abcc6
protein expression in Abcc6 / knock-
out mice (Jiang et al., 2012). Further-
more, the potential correction of
nonsense mutations in the ABCC6
gene by read-through mechanism by
PTC124, a non-aminoglycoside non-
sense mutation suppressor molecule,
has been tested. Preliminary studies
demonstrated that PTC124 enhances
read-through of stop codon muta-
tions in this gene in cell culture
systems, but the efficiency is relatively
low (Y Zhou et al., unpublished). On-
going development of more efficient
molecules for the read-through pur-
poses and subsequent testing of such
compounds in animal models may
provide a novel means to treat PXE
patients who harbor nonsense mutati-
ons in their ABCC6 gene.
Conclusions
PXE is a complex multisystem disorder
at the genome/environment interface.
Although the database on the mutations
in the ABCC6 gene has been expanding
since their first description in 2000, and
novel genes have been discovered with
mutations causing PXE-like phenotypes,
it is clear that the severity of the pheno-
type, the age at onset, and the rate of
progression are modulated by a number
of factors, both genetic and epigenetic,
as well as environmental factors such as
diet and lifestyle variables. It appears
that essentially all clinical manifesta-
tions in the skin, eyes, and the cardio-
vascular system are sequela of
hydroxyapatite deposition in the tissues,
and prevention of these mineralization
processes by approaches, such as diet-
ary supplementation with magnesium,
would be expected to be helpful in the
treatment of these patients. Meanwhile,
further research, including identification
of specific molecules transported by
ABCC6, is necessary for development
of global, pathophysiology-related
approaches to treat this currently intract-
able disorder (Table 2).
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